EU seeks to incentivize antimicrobial drug development as part of proposed pharma reforms

Paul Schloesser

Associate Editor

The EU is planning on introducing some of the largest reforms to pharmaceutical development in the 27-nation bloc later this month. While the entirety of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EU seeks to incentivize antimicrobial drug development as part of proposed pharma reforms

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

EU seeks to in­cen­tivize an­timi­cro­bial drug de­vel­op­ment as part of pro­posed phar­ma re­forms

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

EU seeks to incentivize antimicrobial drug development as part of proposed pharma reforms